Clinical Trial Update: Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating alemtuzumab and clofarabine for relapsed or refractory acute lymphoblastic leukemia was terminated; results were posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• Clofarabine (clofarabine)

Snippet

Sponsor: University of California, San Diego | Conditions: Acute Lymphoblastic Leukemia | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-08-12